Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>Incannex Healthcare is an Australian biotech specializing in the development of treatments for chronic conditions through a unique approach. Specifically, the company is investigating the use of cannabinoids and psychedelics, leveraging its synergistic combination intellectual property (IP). Most recently, it has achieved proof-of-concept in Australia for IHL-42X, its lead asset for the treatment of obstructive sleep apnea (OSA). The company intends to file an investigational new drug application (IND) with the FDA (in CY Q422) following positive Phase II results from its Australian clinical trial data. Incannex is also progressing development of its (Australian) Phase II clinical asset, psilocybin in combination with psychotherapy in generalized anxiety disorder (GAD). We value Incannex at US$695.7m or US$11.42 per ADR.</p>

Incannex Healthcare is an Australian biotech specializing in the development of treatments for chronic conditions through a unique approach. Specifically, the company is investigating the use of cannabinoids and psychedelics, leveraging its synergistic combination intellectual property (IP). Most recently, it has achieved proof-of-concept in Australia for IHL-42X, its lead asset for the treatment of obstructive sleep apnea (OSA). The company intends to file an investigational new drug application (IND) with the FDA (in CY Q422) following positive Phase II results from its Australian clinical trial data. Incannex is also progressing development of its (Australian) Phase II clinical asset, psilocybin in combination with psychotherapy in generalized anxiety disorder (GAD). We value Incannex at US$695.7m or US$11.42 per ADR.

Incannex Healthcare - Addressing unmet needs via alternative approach

<p>Incannex Healthcare, an Australian cannabinoid and psychedelic medicines biotech, has announced that it has completed the acquisition of APIRx Pharmaceuticals (APIRx), a US biotechnology company focused on the development and manufacture of cannabinoid formulations. In an all-share transaction, Incannex has acquired 100% of the issued share capital in APIRx. APIRx’s pipeline consists of 22 clinical and pre-clinical therapeutic cannabinoid development programmes and an extensive intellectual property portfolio of 19 granted patents and 23 patents pending. The deal strengthens Incannex’s market position and provides it with what we believe is one of the sector's most diversified portfolios of medicinal cannabinoid drug formulations and psychedelic treatment regimes. The transaction offers synergies, in terms of both portfolio alignment and route to market strategy for products, and offers Incannex near- and longer-term opportunities.</p>

Incannex Healthcare, an Australian cannabinoid and psychedelic medicines biotech, has announced that it has completed the acquisition of APIRx Pharmaceuticals (APIRx), a US biotechnology company focused on the development and manufacture of cannabinoid formulations. In an all-share transaction, Incannex has acquired 100% of the issued share capital in APIRx. APIRx’s pipeline consists of 22 clinical and pre-clinical therapeutic cannabinoid development programmes and an extensive intellectual property portfolio of 19 granted patents and 23 patents pending. The deal strengthens Incannex’s market position and provides it with what we believe is one of the sector's most diversified portfolios of medicinal cannabinoid drug formulations and psychedelic treatment regimes. The transaction offers synergies, in terms of both portfolio alignment and route to market strategy for products, and offers Incannex near- and longer-term opportunities.

Incannex Healthcare - APIRx acquisition to bolster portfolio

Australia

Incannex Healthcare Limited manufactures medical equipment. The Company offers dental instruments. Incannex Healthcare serves customers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Incannex Healthcare (IHL AU)

Incannex Healthcare - Addressing unmet needs via alternative approach

Incannex Healthcare is an Australian biotech specializing in the development of treatments for chronic conditions through a unique approach....

Edison Investment Research

Incannex Healthcare - APIRx acquisition to bolster portfolio

Incannex Healthcare, an Australian cannabinoid and psychedelic medicines biotech, has announced that it has completed the acquisition of APIRx...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)